The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | CAR T-cell updates in lymphoma and myeloma from ASH 2018
Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, shares her views on the latest real world data on CAR T-cell therapy presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. This includes how axicabtagene ciloleucel transitions from clinical trials into real world practice, the emergence of CD30 as a target, and the surge in CAR T-cell research in China. In the multiple myeloma space, the anti-BCMA CAR T-cell product LCAR-B38M is under investigation (LEGEND-2; NCT03090659).
